NASH registry study aims to map disease in chinese patients

NCT ID NCT06123858

Terminated Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to collect information about Chinese patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Researchers planned to track how the disease is diagnosed and treated in real-world clinics, and to understand patients' knowledge and beliefs about NASH. The study was terminated, so results may be limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH WITH FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH WITH FIBROSIS

Contacts and locations

Show contact details

Locations

Research Site

Beijing, China
Research Site

Changchun, China
Research Site

Chengdu, China
Research Site

Fuzhou, China
Research Site

Guangzhou, China
Research Site

Hangzhou, China
Research Site

Inner Mongolia, China
Research Site

Nanchang, China
Research Site

Qingdao, China
Research Site

Shanghai, China
Research Site

Shenyang, China
Research Site

Taiyuan, China
Research Site

Tianjin, China
Research Site

Wenzhou, China
Research Site

Xi'an, China
Research Site

Zhengzhou, China